Board of Directors May Meeting Highlights

Not: pictured: Jordan S. Orange, MD, PhD, FAAAAI; Allison Ramsey, MD, FAAAAI

The members of the AAAAI Board of Directors met in person May 30-31, 2025, in Seattle, WA, to discuss current and future activities.

The Board of Directors appreciate the work of AAAAI committee members and Chairs as they strive toward achieving the AAAAI mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care. Over the course of the meeting, several significant decisions were made. Here are the highlights:

Approvals

A number of requests were granted approval, including the 2026 Honorary Award recipients, continuation of funding for Discovery and the Chrysalis Project, and an increase in slots for the Chrysalis Project to 70 participants. Funding for a full website audit and continued funding for the AAP 2025 Supplement to Pediatrics “Synopsis Book: Best Articles Relevant to Pediatric Allergy, Asthma, and Immunology,” was also approved.

Additionally, the Board approved continued funding for AAAAI leadership development programs such as the Leadership Institute and the Leadership Development Course to be held at the 2026 AAAAI Annual Meeting.

Presidential Presentations

Frank S. Virant, MD, FAAAAI, provided an update on his presidential focus, including updates for the upcoming Practice Management Course at the 2026 Annual Meeting, and his continued work on developing educational media for primary care physicians and the public on “How the Allergy, Asthma, Immunology Specialist Can Help.” A task force is working on the development of print and online materials to achieve this goal.

Carla M. Davis, MD, FAAAAI, provided a first look at her coming presidential focus, centered on advancing access to the allergy/immunology specialty, including:

Leveraging technology to personalize opportunities within the AAAAI to support a diverse membership.
Evaluating, supporting and strengthening research initiatives.
Influencing policy makers at the Congressional, Regulatory and State Levels to emphasize that patient voices are critical.

Miscellaneous

A number of other projects and topics were discussed, including the first report of the A/I Scientific Community Task Force – the purpose of which is to develop messaging to face the A/I scientific and research community and to assist members in protecting research efforts across the AAAAI and in all areas of scientific research. In addition, the three divisions of the Board of Directors—Education, Practice & Policy and Research & Training—met individually to discuss committee activities. From those meetings, funding was approved for the creation of up to two new 2026 bridge grants for terminated federal programs across any faculty level; funding for the 2027 In-Training Examination Committee, Program Directors Assembly and A/I Division Directors winter meetings; and approval of a new position within the Office of Practice Management to consider opportunities to research and to promote the role of the allergy/immunology specialty in healthcare economics.

What

The next Board of Directors meeting

When

November 21-23, 2025

Where

Washington, DC